Medical Marketing Int'l Group PLC
20 February 2004


FOR IMMEDIATE RELEASE 20 FEBRUARY 2004


MMI TO BE GRANTED

US PATENT FOR ANTI CANCER THERAPY


Medical Marketing International Group plc ('MMI') the Cambridge, UK-based
technology management company focussed on the bio-therapeutic sector (LSE : MMG)
announces that it has been formally notified by the US Patent Office that the
patent for its ruthenium anti-cancer therapy, being developed by MMI's
wholly-owned cancer therapy subsidiary Oncosense, will be granted.

MMI announced on 28th October 2003 that it had received notification by the
European Patent Office that the ruthenium patent would be granted in the
European territories.

On 18th September 2003 MMI announced that the Oncosense ruthenium compounds had
the potential to be a whole new class of cancer therapy showing potency at least
as good as the market-leading therapies carboplatin and cisplatin and with the
potential for reduced toxicity, a novel mechanism of action and non-cross
resistance. Additionally data showed that the ruthenium compounds each have
their own spectrum of activity, with individual compounds showing differential
activity against individual cell lines including non-small cell lung cancer,
breast cancer and melanoma.

Mark Burton, Technology Manager at MMI, commenting on today's announcement said:
'We are delighted to have received notification that the ruthenium patent will
grant in the world's biggest cancer therapy market. When added to the European
patent notification this means that we will have protection in two of the
world's largest markets. This news coupled with our technical progress with
ruthenium considerably strengthens our commercial position in the global cancer
therapy market which is worth some $20bn'.


For further information, please contact:

David Best - Executive Chairman
MMI Group Tel: +44 (0)1223 477677

www.mmigroup.co.uk

Lisa Baderoon
Buchanan Communications Tel: +44 (0)20 7466 5000
lisab@buchanan.uk.com


This information is provided by RNS
The company news service from the London Stock Exchange

after a dip today i took the opportunity to buy ... were down 4p today on profit taking but now heading back ..worth looking into for the coming months... here are the last set of results and more info about this company ..dyor etc etc


Medical Marketing Int'l Group PLC
19 December 2003

Immediate Release 19 December 2003


MEDICAL MARKETING INTERNATIONAL GROUP PLC (MMI)

INTERIM RESULTS ANNOUNCEMENT
For the six months ended 30 September 2003

Cambridge, UK, 19 December 2003, Medical Marketing International Group plc 'MMI'
(LSE: MMG), the global technology management company today announced its interim
results for the six months ended 30th September 2003.

HIGHLIGHTS

Significant progress in Oncosense cancer therapy subsidiary
Significant progress in Viratis HIV/AIDS therapy joint venture
Investment progress in BioScience VCT
Strengthening of NHS client relationships
Bioscience Innovation Centre launches Lab Hotel(R)
Institutional placing raises 1.86m in November 2003

FINANCIAL HIGHLIGHTS

Administrative expenses reduced by 8%
Excluding development costs in subsidiaries - administrative
expenses reduced by 16%
Operational loss (excluding development costs of Oncosense/ Viratis/
Endozyme/ Blaven) reduced by 10%
Revenue from BioScience VCT maintained
Bioscience Innovation Centre income maintained
Post placing cash balances of 2.2m

David Best, Executive Chairman said:-

'With a strong portfolio and pipeline, with a lean and established business
model and good cash reserves, we look forward to the future with confidence.'


For further information, contact:

David Best - Executive Chairman
MMI Group Tel: +44 (0)1223 477677

www.mmigroup.co.uk

Lisa Baderoon lisab@buchanan.uk.com
Buchanan Communications Tel: +44 (0)20 7466 5000


CHAIRMAN'S STATEMENT


I am delighted to be able to report that MMI has made significant progress in
most aspects of its business during the first six months of the current
financial year, and in particular in its 'bio baby' portfolio. Similarly our
investment in the BioScience VCT is continuing to add to our income and the Fund
has started to make investments. The difficult operating conditions and the
reduction in bank interest received lead to a reduction in income. Despite this,
excluding the increased development costs in our biobabies, we have been able to
reduce our operating loss by 10% by keeping our underlying costs under control.
Our focus on areas of unmet medical need, such as cancer and AIDS, coupled with
the lowest cost-base in the sector has lead, we believe, to a partial recovery
in the Company's share price where we are currently the peer group leader. In
addition, the MMI business model has attracted institutional investor interest
enabling us to successfully raise, in November 2003, 1.86m from existing and
new institutional shareholders thus adding to our cash balances which are now
sufficient for our current needs.


In Oncosense, our wholly-owned cancer therapy subsidiary, we now have over 20
compounds based on the metal ruthenium. Most of these compounds have now been
shown to be highly active against human tumour models, in most cases as active
or more active than the class-leading therapies based on the metal platinum. We
now know that each compound has its own activity profile and this, coupled with
encouraging toxicity data leads us to believe that we may have the potential for
a whole new class of cancer therapies with activity against most tumour types,
including those that are currently difficult to treat. Our commercial position
with ruthenium was also strengthened by the news that patents in Europe will be
granted. Significant progress was also made with our pineapple extracts which
have now been purified, successfully tested on human cancer cells and which are
currently being tested on in-vivo models. We anticipate further progress towards
clinical trials with both these programmes during the coming year.


Viratis, our joint-venture with Kings and Queen Mary College, London has now
shown that the ribozyme-based anti-viral therapy has a high level of penetration
into human cells resulting in a significant reduction of HIV/AID's viruses in
the cell. Again we anticipate further progress to clinical trials in the next
year. Given the considerable progress in both Oncosense and Viratis we decided
it was in shareholders interests to use MMI funds and resources to secure these
developments rather than dilute our holdings in these subsidiaries by bringing
in third party funding. This use of MMI's human and financial resources is
likely to increase as we get closer to clinical trials.


MMI's fee income from the BioScience VCT was maintained and now that the Fund
has started to invest, we anticipate a significant increase in fees for our due
diligence service, Tek-check(R). Similarly, as investment sentiment improves
within the life sciences sector, we also expect to increase our provision of the
Tek-check(R) service for other investment organisations which require a third
party evaluation of a technology or company prior to investment and as part of
their due diligence strategy.


We have continued to grow our technology management business for NHS clients,
and in particular with the National Blood Service (NBS). We have now completed
our first technology audit for the Bristol laboratories of NBS. The technology
audit has reviewed all the research and development at this, the first of
fifteen NBS laboratory sites, and has identified areas of commercial potential.
This first audit has lead to a number of licensing deals for NBS and may
potentially lead to a number of spin-out companies in the future. The European
Clinical Trials Directive will become UK law on 4th May 2004 and, amongst other
things, will mean that clinical trials must use medicines manufactured to GMP
standards. NBS has one of the only accredited GMP manufacturing facilities in
the public sector and together we intend to grow the income from this and
collaborate further with NBS to facilitate the entry of biopharmaceuticals to
early clinical trials. We will also roll-out the technology audit programme to
other NBS sites starting in Cambridge.


Our Bioscience Innovation Centre (BIC) continued to enjoy 80% occupancy and
rental income was maintained despite the very slow business property market. The
provision of specialist laboratory space and skill in BIC has given us an
advantage over general property offerings and we have now begun to implement our
Lab Hotel(R) plans. Lab Hotel(R) will allow young biotech companies to have access
to state-of-the-art equipment on a short-term rental basis. The equipment will
be supplied to MMI by global leaders in laboratory equipment and operated by
MMI's staff to the highest industrial standards giving young companies the ideal
resources vital to their success. In the short-term, this will mean as planned,
a reduction in rental income as we take back space, previously sub-let to
non-biotech companies. We believe that Lab Hotel(R) will enable us to turn BIC
into the place to start a biotech company, right at the heart of Europe's
largest technology cluster. The continued development of BIC should lead to
increased income and further opportunities to take equity stakes in exciting
biotech businesses. Lab Hotel(R) has already reached agreement with Pall
Biomedical, a world leader in filtration systems and other agreements are
expected to follow.


During the last few years, technology shares have been under considerable
pressure. MMI's focus on areas of unmet medical need such as cancer and AIDS,
coupled with our continued downward pressure on costs, has we believe lead to a
partial recovery in our value. We have lead and continue to lead the share price
recovery in our peer group and we hope that investors will increasingly
recognise the strength and value in MMI's business model. We continue to have no
bank borrowings and following the institutional placing we have sufficient funds
for our current needs.


Although operating conditions are likely to remain difficult in the short term,
we expect there to be significant progress in our existing portfolio of
biobabies and we are currently exploring a number of exciting opportunities that
might add to the strength and value of the portfolio. We are encouraged by the
Chancellor's pre-budget statement which underlines his commitment to the VCT
sector and we therefore expect further progress with the Bioscience VCT should
the Chancellor's actions lead to an increase in funds invested in VCT's. In
addition we continue to explore opportunities to build on the technology advisor
aspects of our business and our due diligence service towards becoming fund
managers. We will continue to develop our Bioscience Innovation Centre as we add
our Lab Hotel(R) facility to our Tek-Assist and MTS programmes with the aim of
creating a global centre of excellence that attracts the very best
bio-therapeutic start-ups to our portfolio.


With a strong portfolio and pipeline, with a lean and established business model
and good cash reserves, we look forward to the future with confidence.

Medical Marketing International (MMG) is tipped as a buy in Shares Magazine this week. It is moving towards profitablity over the next 18 months. Recently it also annouced a major extension to its contract with the Blood transfusion services of the NHS. The December interim statement was bullish.

Mike Walters tipped these last night....under Best Bet......could be worth 100p or more if all goes according to plan..

Thanks Mitzy. I saw the tip. Let it run to 100p and onwards

Two main Directors selling shares--is this a bad sign?

THey sold to the Prudential and M & G securities ..a good sign when institutions want a piece of the action.

Big institutions are coming in.

Some large buying this past week could it be that Prudential are buying more...

It is on the uptrend lately. Is there any news?

Nothing as yet although the institutions are picking them up so there is something happening behind the scenes..

I am a long term holder of mmg since its day's as Bioscience innovation on ofex. Have topped up occasionaly along the way (unfortunately not at 2p)

I would like to hear the views of any chartists on this stock. There seems to be a fairly stronger lower resistance line looking at the one year chart.

Not a chartist myself rob but the chart trendline is still intact so the price could hit a high of 70p..

i have been told that there is news due inthis stock in the next 10 days, i have not followed this one. can someone update on any expected news

Dr Best is back from his holiday and the gossip is he will announce some news on their anti-cancer drug within the the next few days...up 10% today on anticipation of the news.

Thanks. my broker said it is from a good source and is expected inthe next 10 days

european patenet announced

The outlook of ruthenium compounds is outstanding. Buy MMI at 76p.

Another big rise on no new news.. whats happening..?